Compare · APD vs CDXS
APD vs CDXS
Side-by-side comparison of Air Products and Chemicals Inc. (APD) and Codexis Inc. (CDXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- APD operates in Basic Materials, while CDXS operates in Industrials - the two are in different parts of the market.
- APD is the larger of the two at $61.63B, about 260.3x CDXS ($236.8M).
- APD has been more active in the news (3 items in the past 4 weeks vs 1 for CDXS).
- APD has more recent analyst coverage (25 ratings vs 12 for CDXS).
- Company
- Air Products and Chemicals Inc.
- Codexis Inc.
- Price
- $276.77-1.99%
- $2.60+2.36%
- Market cap
- $61.63B
- $236.8M
- 1M return
- -
- +0.39%
- 1Y return
- -
- +9.01%
- Industry
- Major Chemicals
- Major Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2010
- News (4w)
- 3
- 1
- Recent ratings
- 25
- 12
Air Products and Chemicals Inc.
Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, equipment, and services worldwide. The company produces atmospheric gases, including oxygen, nitrogen, argon, and rare gases; process gases, such as hydrogen, helium, carbon dioxide, carbon monoxide, syngas, and specialty gases; and equipment for the production or processing of gases comprising air separation units and non-cryogenic generators for customers in various industries, including refining, chemical, gasification, metals, manufacturing, food and beverage, electronics, magnetic resonance imaging, energy production and refining, and metals. It also designs and manufactures equipment for air separation, hydrocarbon recovery and purification, natural gas liquefaction, and liquid helium and liquid hydrogen transport and storage. Air Products and Chemicals, Inc. has a strategic collaboration with Baker Hughes Company to develop hydrogen compression systems. The company was founded in 1940 and is headquartered in Allentown, Pennsylvania.
Codexis Inc.
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Latest APD
- Air Products Membrane Solutions Holds Ribbon-Cutting Event for $70 Million Expansion of its Missouri Manufacturing and Logistics Center
- SEC Form SD filed by Air Products and Chemicals Inc.
- Air Products to Speak at Bernstein Strategic Decisions Conference on May 27
- Exec Vice President and CFO Schaeffer Melissa N. sold $824,405 worth of shares (2,714 units at $303.76), decreasing direct ownership by 16% to 14,212 units (SEC Form 4)
- Air Products to Showcase Technology Solutions for Sustainable Iron and Steel Production at AISTech2026
- Air Products upgraded by BMO Capital Markets with a new price target
- SEC Form 10-Q filed by Air Products and Chemicals Inc.
- Air Products and Chemicals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Air Products Reports Fiscal 2026 Second Quarter Results
- Air Products to Expand Industrial Gas Supply for Samsung Electronics' Next-Generation Semiconductor Fab in South Korea
Latest CDXS
- Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
- SEC Form 10-Q filed by Codexis Inc.
- Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Codexis Reports First Quarter 2026 Financial Results
- Codexis to share RNA manufacturing advances at TIDES USA
- SEC Form DEFA14A filed by Codexis Inc.
- SEC Form DEF 14A filed by Codexis Inc.
- Codexis to Report First Quarter 2026 Financial Results on May 7
- SEC Form 8-K filed by Codexis Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Codexis Inc.